Bromocriptine mesylate
- CAS No.
- 22260-51-1
- Chemical Name:
- Bromocriptine mesylate
- Synonyms
- BCT;BRC;Bromocryptine mesylate;Bromocriptine-13C-d3 Mesylate;Bromocriptine Mesylate (150 mg);Bagren;cb-154;Pravidel;Serono-Bagren;CB-154 mesylate
- CBNumber:
- CB4335584
- Molecular Formula:
- C33H44BrN5O8S
- Molecular Weight:
- 750.7
- MOL File:
- 22260-51-1.mol
- MSDS File:
- SDS
- Modify Date:
- 2023/9/26 16:29:58
| Melting point | 192-196° (dec) |
|---|---|
| alpha | D20 +95° (c = 1 in methanol-methylene chloride) |
| storage temp. | 2-8°C |
| solubility | H2O: 0.8 mg/mL |
| form | solid |
| pka | 4.90(at 25℃) |
| color | white |
| optical activity | [α]20/D +95°, c = 1 in methanol: methylene chloride (1:1)(lit.) |
| Merck | 13,1400 |
| BRN | 4115238 |
| Stability | Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months |
| InChIKey | NOJMTMIRQRDZMT-JGYCFGIMSA-N |
| CAS DataBase Reference | 22260-51-1(CAS DataBase Reference) |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |   GHS07,GHS09 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Signal word | Warning | |||||||||
| Hazard statements | H302-H410 | |||||||||
| Precautionary statements | P273-P301+P312+P330 | |||||||||
| Hazard Codes | Xn | |||||||||
| Risk Statements | 20/21/22 | |||||||||
| Safety Statements | 22-24/25-36 | |||||||||
| RIDADR | UN 3077 9 / PGIII | |||||||||
| WGK Germany | 3 | |||||||||
| RTECS | KE1595000 | |||||||||
| F | 3-10 | |||||||||
| HS Code | 29396900 | |||||||||
| Toxicity | LD50 in mice, rats, rabbits (mg/kg): 190, 72, 12.5 i.v. (Parkes) | |||||||||
| NFPA 704 |
|
Bromocriptine mesylate price More Price(3)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Sigma-Aldrich(India) | B2134 | 2-Bromo-α-ergocryptine methanesulfonate salt solid | 22260-51-1 | 25MG | ₹9190.43 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | B2134 | 2-Bromo-α-ergocryptine methanesulfonate salt solid | 22260-51-1 | 100MG | ₹24735.13 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | B2134 | 2-Bromo-α-ergocryptine methanesulfonate salt solid | 22260-51-1 | 250MG | ₹48864.05 | 2022-06-14 | Buy |
Bromocriptine mesylate Chemical Properties,Uses,Production
Description
Bromocriptine is a dopamine receptor agonist (Kis = 1,659, 12.2, 12.2, 59.7, and 1,691 nM for dopamine D1, D2, D3, D4, and D5 receptors, respectively). It also binds to the serotonin (5-HT) receptor subtypes 5-HT1A and 5-HT1D (Kis = 12.9 and 10.7 nM, respectively), as well as α1-adrenergic receptors (Kis = 1.12-4.17 nM). Bromocriptine (5 mg/kg) restores locomotor activity, without inducing dyskinesia, in a macaque model of Parkinson’s disease induced by MPTP. Formulations containing bromocriptine have been used in the treatment of Parkinson''s disease, hyperprolactinemia-associated dysfunctions, and acromegaly.
Chemical Properties
Solid
Uses
Dopamine receptor agonist; derivative of the ergotoxin group of ergot alkaloids. Prolactin inhibitor; antiparkinsonian.
General Description
Bromocriptine mesylate,(6aR,9R)-5-bromo-N-((2R,5S,10aS,10bS)-10b-hydroxy-5-isobutyl-2-isopropyl-3,6-dioxooctahydro-2H-oxazolo[3,2-a]pyrrolo[2,1c]pyrazin-2-yl)-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide methanesulfonate(Parlodel), is a white solid soluble in ethanol and slightly solublein water (pKa’s＝6.6 and 15). Bromocriptine is rapidlyabsorbed after oral administration and it has low systemicbioavailability because of its extensive first-pass metabolism.Bromocriptine enters the brain quickly with a half-lifefor uptake into the brain of approximately 0.3 hours; 8% ofthe drug crosses the BBB.The metabolites are excreted primarilyin the bile and feces. The high first-pass hepatic metabolismimplies an increased risk of drug interactions.Concomitant administration with the DA antagonists, metoclopramide,or domperidone may aggravate parkinsoniansymptoms and induce extrapyramidal side effects (EPS).Other drugs that may interact with bromocriptine are highlyplasma protein–bound drugs (e.g., warfarin, increased dyskinesiacaused by bromocriptine); macrolides antibacterials(enhanced dopaminergic effects); and caffeine (elevation inplasma bromocriptine concentrations). The combination oflevodopa/AADC inhibitors with bromocriptine permits a reductionof the dose of levodopa. Thus, the side effects oflevodopa are decreased, resulting in a more continuous stimulationof DA receptors.
Biological Activity
Selective D 2 -like dopamine receptor agonist (K i values are ~ 8, ~ 5, ~ 290, ~ 440 and ~ 450 nM for D 2 , D 3 , D 4 , D 1 and D 5 receptors respectively).
Bromocriptine mesylate Preparation Products And Raw materials
| Supplier | Tel | Country | ProdList | Advantage | Inquiry |
|---|---|---|---|---|---|
| CLEARSYNTH LABS LTD. | +91-22-45045900 | Hyderabad, India | 6351 | 58 | Inquiry |
| A.J Chemicals | 91-9810153283 | New Delhi, India | 6124 | 58 | Inquiry |
| Pharma Affiliates | 172-5066494 | Haryana, India | 6761 | 58 | Inquiry |
| SynZeal Research Pvt Ltd | +1 226-802-2078 | Gujarat, India | 6522 | 58 | Inquiry |
| Pharmaffiliates Analytics and Synthetics P. Ltd | +91-172-5066494 | Haryana, India | 6773 | 58 | Inquiry |
| Astitva Chemicals | 08048262675 | Gujarat, India | 90 | 58 | Inquiry |
| Global Chem Asia Pacific | 91-9849161572 | Hyderabad, India | 255 | 58 | Inquiry |
| Maas Pharma Chemicals | +91-9958666224 | Delhi, India | 1607 | 58 | Inquiry |
| Dr. Ashavin's Lab Services(OPC) Private Limited | 91--9855611075 | Punjab, India | 3 | 58 | Inquiry |
| Aaditya Pharmachem | 91-8037401177 | Maharashtra, India | 9 | 58 | Inquiry |
22260-51-1(Bromocriptine mesylate)Related Search:
1of4
chevron_right